Cognizant has announced an extension of its partnership with Gilead Sciences, which will see Cognizant lead digital transformation at Gilead, among additional expansions, for a total expected value of US$800m over the following five years. Gilead will use these advancements to market medicine for HIV, viral hepatitis and cancer.
A partnership to advance healthcare technology
Leading IT service Cognizant aims to engineer modern businesses and support clients as they seek to use modern technology in their work. The company has 319,000 employees and a revenue of US$16bn.
Biotechnology research company Gilead Sciences was founded in 1987 and is headquartered in Foster City, California.
Cognizant will support Gilead Sciences, by:
- Enabling Gilead to provide a more consistent and seamless experience to over 18,000 internal users across 40 countries
- Gilead Sciences’ applications will be modernised on Cloud Platforms
- Generative AI (GenAI) and AI automation will be used to expand Gilead’s customer service experience
- Cognizant will build applications and operate services that introduce new or enhanced technologies for efficient business capabilities
- Finally, Cognizant will support enterprise data and analytics platforms across all business functions.
AI digital transformation to assist marketing medicine for cancer, HIV & more
Srinivas Shankar, Global Head, Life Sciences, Chief Commercial Officer for the Americas at Cognizant, was proud to announce an expansion of the relationship between Cognizant Life Sciences and Gilead Sciences.
“Under the new agreement, Cognizant will manage Gilead’s global IT infrastructure, platforms, applications and advanced analytics and lead initiatives designed to accelerate its digital transformation,” Shankar said. “We anticipate leveraging the power of Generative AI (GenAI) and AI automation to help enhance Gilead’s customer service experience and assist it in driving greater manufacturing efficiencies. The agreement includes renewal and expansion of Cognizant services for a total expected value of US$800m over the next five years.
“This partnership is about helping Gilead streamline parts of its business with the goal of faster time to market of various medicines for life-threatening diseases, including HIV, viral hepatitis and cancer.”
“I am happy to share that Gilead and Cognizant are extending our partnership to enable stable, secure operations and advance Gilead’s digital transformation, including in advanced analytics,” said Marc Berson, Senior Vice President, Chief Information Officer at Gilead Sciences. “Through this collaboration, we will streamline various parts of Gilead’s business with the goal of faster time-to-market of medicines for life-threatening diseases, including HIV, viral hepatitis and cancer.”
For more insights into Healthcare – check out the latest edition of Healthcare Digital and be sure to follow us on LinkedIn & Twitter.
Other magazines that may be of interest – Manufacturing Magazine.
*********************************************
BizClik is a global provider of B2B digital media platforms that cover ‘Executive Communities’ for CEO’s, CFO’s, CMO’s, Sustainability Leaders, Procurement & Supply Chain Leaders, Technology & AI Leaders, Cyber Leaders, FinTech & InsurTech Leaders as well as covering industries such as Manufacturing, Mining, Energy, EV, Construction, Healthcare + Food & Drink.
BizClik, based in London, Dubai & New York offers services such as Content Creation, Advertising & Sponsorship Solutions, Webinars & Events.
